Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
01. Oktober 2024 07:00 ET
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.